DOSTINEX TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
24-07-2013
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CABERGOLINE
Fáanlegur frá:
PFIZER CANADA ULC
ATC númer:
G02CB03
INN (Alþjóðlegt nafn):
CABERGOLINE
Skammtar:
0.5MG
Lyfjaform:
TABLET
Samsetning:
CABERGOLINE 0.5MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
8
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0141281001; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2001-03-02
Vara einkenni
PRODUCT MONOGRAPH
PR
DOSTINEX
®
(cabergoline)
Tablets 0.5 mg
Dopamine Receptor Agonist
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
REVISION DATE:
23 JULY 2013
Dist. by: Paladin Labs Inc.
St-Laurent, Quebec H4P 2T4
CONTROL NO. 164062
®
Pharmacia & Upjohn S.P.A.
Pfizer Canada Inc., Licensee
© Pfizer Canada Inc. 2013
_ _
_DOSTINEX* (cabergoline) Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND STABILITY
..........................................................................................18
SPECIAL HANDLING INSTRUCTIONS
.......................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
.................................................................
Lestu allt skjalið
